GLS and renal carcinoma: GPX4 and glutaminase inhibitors can inhibit pyrimidine synthesis and increase ROS levels in VHL-deficient renal carcinoma cells, and the PARP inhibitor olaparib and glutaminase inhibitors can synergistically inhibit the growth of these cells in vivo and in vitro.